secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001193125-25-263491
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology Q3 net loss $74.1M; progress on ziftomenib Phase 3 trials
-----------------------------------------------------------------------

- Net loss of $74.1M in Q3 2025 vs $54.4M in Q3 2024; R&D spend rose to $67.9M.
- Collaboration revenue of $20.8M from Kyowa Kirin partnership; no revenue in prior year.
- Pro forma cash $609.7M; cash runway into 2027 supports ziftomenib program through KOMET-017 topline.
- First patients dosed in KOMET-017 Phase 3 (frontline AML) and FLT3 inhibitor cohort of KOMET-007.
- PDUFA target date Nov 30, 2025 for ziftomenib in R/R NPM1-m AML; two oral ASH 2025 abstracts.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000119312525263491/0001193125-25-263491-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000119312525263491/kura-20251104.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-263491

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer